These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33786273)

  • 1. Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Tobe K; Maegawa H; Nakamura I; Uno S
    Diabetol Int; 2021 Apr; 12(2):181-196. PubMed ID: 33786273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
    Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
    Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world evidence for long-term safety and effectiveness of ipragliflozin in treatment-naïve versus non-naïve Japanese patients with type 2 diabetes mellitus: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Maegawa H; Tobe K; Nakamura I; Uno S
    Diabetol Int; 2021 Oct; 12(4):430-444. PubMed ID: 34567926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 May; 12(5):1359-1378. PubMed ID: 33730336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).
    Nakamura I; Maegawa H; Tobe K; Uno S
    Expert Opin Pharmacother; 2021 Feb; 22(3):373-387. PubMed ID: 33012212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Adv Ther; 2019 Apr; 36(4):923-949. PubMed ID: 30767112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
    Maegawa H; Tobe K; Tabuchi H; Nakamura I; Uno S
    Expert Opin Pharmacother; 2018 Mar; 19(4):327-336. PubMed ID: 29388470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.
    Yokote K; Terauchi Y; Nakamura I; Sugamori H
    Expert Opin Pharmacother; 2016 Oct; 17(15):1995-2003. PubMed ID: 27477242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study.
    Maegawa H; Tobe K; Nakamura I; Uno S
    Curr Med Res Opin; 2019 Nov; 35(11):1901-1910. PubMed ID: 31347926
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Kaku K
    J Diabetes Investig; 2020 Jan; 11(1):132-141. PubMed ID: 31197929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Tobe K; Maegawa H; Nakamura I; Uno S
    Endocr J; 2021 Aug; 68(8):905-918. PubMed ID: 33827996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
    Terauchi Y; Yokote K; Nakamura I; Sugamori H
    Expert Opin Pharmacother; 2016; 17(4):463-71. PubMed ID: 26800061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study.
    Yamamoto F; Ikeda R; Ochiai K; Hirase T; Hayashi N; Okamura T
    Diabetes Ther; 2020 Feb; 11(2):523-533. PubMed ID: 31933070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.
    Haneda M; Kadowaki T; Ito H; Sasaki K; Hiraide S; Ishii M; Matsukawa M; Ueno M
    Diabetes Ther; 2018 Jun; 9(3):1083-1097. PubMed ID: 29637459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.
    Ferrannini E; Veltkamp SA; Smulders RA; Kadokura T
    Diabetes Care; 2013 May; 36(5):1260-5. PubMed ID: 23359360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus.
    Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
    Diabetes Ther; 2020 Apr; 11(4):951-964. PubMed ID: 32166619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus.
    Kashiwagi A; Kazuta K; Yoshida S; Nagase I
    J Diabetes Investig; 2014 Jul; 5(4):382-91. PubMed ID: 25411597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.
    Ito D; Ikuma-Suwa E; Inoue K; Kaneko K; Yanagisawa M; Inukai K; Noda M; Shimada A
    J Clin Med Res; 2017 Feb; 9(2):154-162. PubMed ID: 28090231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials.
    Kashiwagi A; Shestakova MV; Ito Y; Noguchi M; Wilpshaar W; Yoshida S; Wilding JPH
    Diabetes Ther; 2019 Dec; 10(6):2201-2217. PubMed ID: 31606880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study.
    Yamamoto F; Unno Y; Okamura T; Ikeda R; Ochiai K; Hayashi N
    Diabetes Ther; 2020 Jan; 11(1):107-117. PubMed ID: 31713160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.